Cytokinetics (CYTK) Earnings Date, Estimates & Call Transcripts $33.04 -0.93 (-2.74%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$33.90 +0.87 (+2.62%) As of 08:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Cytokinetics Earnings Summary Latest Q1 Earnings DateMay. 6EstimatedConsensus EPS (May. 6) -$1.41 Actual EPS (May. 6) -$1.36 Beat By $0.05 Actual Revenue (May. 6) $1.60MCytokinetics posted Q1 2025 earnings on May 6, 2025, reporting an EPS of -$1.36, which beat the consensus estimate of -$1.41 by $0.05. Quarterly revenue rose 89.1% year-over-year to $1.60 million, below analyst estimates of $2.77 million. With a trailing EPS of -$5.26, Cytokinetics' earnings are expected to decrease next year, from ($5.24) to ($5.25) per share. Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Cytokinetics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytokinetics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCYTK Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CYTK Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Cytokinetics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$1.46-$1.42-$1.44Q2 20252-$1.44-$1.40-$1.42Q3 20252-$1.44-$1.44-$1.44Q4 20252-$1.53-$1.34-$1.44 Cytokinetics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025-$1.41-$1.36+$0.05-$1.36$2.77M$1.60M2/27/2025Q4 2024-$1.29-$1.26+$0.03-$1.26$14.26M$16.93M11/6/2024Q3 2024-$1.27-$1.36 -$0.09-$1.36$1.21M$0.46M8/8/2024Q2 2024-$1.06-$1.31 -$0.25-$1.31$7.61M$0.25M5/8/2024Q1 2024-$1.16-$1.33 -$0.17-$1.33$0.91M$0.84M2/27/2024Q4 2023-$1.03-$1.38 -$0.35-$1.38$7.62M$1.70M11/2/2023Q3 2023-$0.72-$1.35 -$0.63-$1.35$24.71M$0.38M8/3/2023Q2 2023-$1.23-$1.34 -$0.11-$1.34$5.67M$0.87M Cytokinetics Earnings - Frequently Asked Questions When did Cytokinetics announce their last quarterly earnings? Cytokinetics (NASDAQ:CYTK) last announced its quarterly earning data on Tuesday, May 6, 2025. Learn more on CYTK's earnings history. Did Cytokinetics beat their earnings estimates last quarter? In the previous quarter, Cytokinetics (NASDAQ:CYTK) reported ($1.36) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.41) by $0.05. Learn more on analysts' earnings estimate vs. CYTK's actual earnings. How can I listen to Cytokinetics's earnings conference call? The conference call for Cytokinetics's latest earnings report can be listened to online. Listen to Conference Call How can I read Cytokinetics's conference call transcript? The conference call transcript for Cytokinetics's latest earnings report can be read online. Read Transcript How much revenue does Cytokinetics generate each year? Cytokinetics (NASDAQ:CYTK) has a recorded annual revenue of $18.47 million. How much profit does Cytokinetics generate each year? Cytokinetics (NASDAQ:CYTK) has a recorded net income of -$526.24 million. CYTK has generated -$5.26 earnings per share over the last four quarters. What is Cytokinetics's EPS forecast for next year? Cytokinetics's earnings are expected to decrease from ($5.24) per share to ($5.25) per share in the next year. More Earnings Resources from MarketBeat Related Companies ITCI Earnings GMAB Earnings RDY Earnings MRNA Earnings ASND Earnings VTRS Earnings QGEN Earnings ROIV Earnings RVMD Earnings LNTH Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Disney Stock Jumps on Earnings—Is the Magic Sustainable?Archer Stock Eyes Q1 Earnings After UAE UpdatesFord Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostPalantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? This page (NASDAQ:CYTK) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredSilver’s 332% Surge?Silver has quietly become one of the most promising investments of this cycle. Russia is now stockpiling silve...Lear Capital | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy cytk Stock Free cytk Stock Alerts